Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic transplantation using peripheral blood stem cells.

N H Russell1, J L Byrne

  • 1Department of Haematology, Nottingham City Hospital NHS Trust, UK.

Best Practice & Research. Clinical Haematology
|April 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

Clinical lymphoma, myeloma & leukemia·2021
Same author

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Leukemia·2018
Same author

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bone marrow transplantation·2017
Same author

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Leukemia·2017
Same author

Deficiencies in postgraduate training for healthcare professionals who provide diabetes education and support: results from the Diabetes Attitudes, Wishes and Needs (DAWN2) study.

Diabetic medicine : a journal of the British Diabetic Association·2017
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Peripheral blood stem cells (PBSC) are increasingly used in allogeneic transplants, showing improved survival and faster recovery. However, PBSC transplants also carry a higher risk of chronic graft-versus-host disease.

Area of Science:

  • Hematology
  • Transplantation immunology

Background:

  • Peripheral blood stem cell (PBSC) use in allogeneic transplantation has significantly increased over the past nine years.
  • In 1999, PBSC accounted for over 50% of sibling and 25% of unrelated donor transplants reported to the EBMT.

Purpose of the Study:

  • To evaluate the impact of increased PBSC use in allogeneic transplantation.
  • To analyze survival outcomes, engraftment, and graft-versus-host disease (GVHD) risks associated with PBSC compared to bone marrow transplants.

Main Methods:

  • Analysis of data from the European Group for Blood and Marrow Transplantation (EBMT).
  • Review of evidence from randomized trials comparing PBSC and bone marrow stem cell sources.
  • Assessment of engraftment times, transplant-related mortality, relapse rates, and chronic GVHD incidence.

Related Experiment Videos

Main Results:

  • PBSC transplantation demonstrates rapid hematopoietic recovery, mirroring benefits seen in autologous transplantation.
  • Randomized trials indicate a survival advantage for PBSC in advanced leukemia, linked to reduced transplant-related mortality and possibly lower relapse rates.
  • A significant increase in chronic graft-versus-host disease risk is associated with PBSC transplantation.

Conclusions:

  • PBSC transplantation offers advantages in engraftment and survival for certain leukemia patients.
  • The increased risk of chronic GVHD with PBSC requires further investigation for long-term outcome assessment.
  • Continued follow-up is necessary to fully understand the long-term implications of PBSC use in allogeneic transplantation.